Mexico’s Health Care Agency Alleges Zimmer Fraud

Mexico’s health care agency is suing Zimmer Biomet for a refund on purchases it made from the company during a long-running bribery scheme. The agency claims the bribery, which was admitted in a 2017 settlement with the US government, nullified its contracts with the device maker.

Mexico
• Source: Shutterstock

Zimmer Biomet Holdings Inc. should refund Mexico’s government for more than $2.6m in illicit profits, the Instituto Mexicano del Seguro Social (Mexican Institute of Social Security, or IMSS) alleged in a lawsuit filed on 30 January in an Indiana federal court. IMSS, which provides health care services in Mexico, is suing to recoup what it spent on products made by Zimmer Biomet and its predecessor, Biomet Inc., during what the agency says was a widespread and long-running bribery scheme. Zimmer merged with Biomet in 2015. (Also see "Zimmer, Biomet Sell Off Some U.S. Assets As They Finalize A $14 Bil. Merger" - Medtech Insight, 25 June, 2015.)

The companies have settled charges that they violated overseas bribery laws with the US Securities and Exchange Commission and Department...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Latin America

El Salvador Sets Up New Regulatory Body To Oversee Medicines & Devices

 

El Salvador has approved a new law that will establish a new regulatory body responsible for authorizing medicines and setting prices.

News We’re Watching: Quidel Recall, Partnerships For Teladoc And Lifebit, Alaris Cybersecurity Issues

 

This week, Quidel recalled the Triage cardiac panel due to a risk of false results; Teladoc and Lifebit announced new partnerships; and, a court upheld a false advertising verdict against Natera, but struck the financial penalties.

News We’re Watching: New CDC Director, Endologix Study Success, Hospital Closure Linked To Ransomware

 
• By 

This week, North Carolina health secretary Mandy Cohen was named the new head of the CDC; Congress debated PAHPA reauthorization; Cala Health launched a Parkinson’s Disease wearable; and IHealth.io was fined for consumer privacy violations.

FDA Investigating Disposable Gloves From Hundreds Of Foreign Companies Because Of Reprocessing Fears

 
• By 

The US FDA says it’s “investigating certain imported medical gloves that appear to have been reprocessed, cleaned, or recycled and sold as new.” The 270 firms in question are listed on an import alert that says their gloves are subject to Detention without Physical Examination.

More from Geography

Pilot To Program: FDA Issues Accreditation Scheme For Conformity Assessment Draft Guidances

 

The US FDA has published a trio of draft guidance documents for its Assessment Scheme for Conformity Program, which began as a pilot in September 2020 to capitalize on the role of standards in the regulation of medical devices.

Biocomposites Fully Acquires SYNICEM And Subiton Lines, Launches NanoBone In UK

 

UK-based Biocomposites will begin selling in the UK its next-generation osteoinductive bone graft substitute, NanoBone, which came with its acquisition of Artoss GmbH in June 2023. Meanwhile, the company has purchased remaining shares in the manufacturers of SYNICEM and Subiton antibiotic bone cements and preformed antibiotic-loaded spacers.

Senseonics Readies For US Launch Of 'World’s First One-Year CGM'

 

US FDA has greenlighted Senseonics’ Eversense 365 continuous glucose monitor, which must be replaced just once a year. Capable of being integrated with compatible insulin pumps as part of an automated insulin delivery system, the fully implantable device lasts 185 days longer than the Eversense E3 sensor and far outstrips competing CGMs, which last only for 10-14 days.